LLY

992.82

+1.74%↑

JNJ

225.45

+2.18%↑

ABBV

208.78

+2.94%↑

UNH

389.05

+2.46%↑

AZN

185.25

+1.17%↑

LLY

992.82

+1.74%↑

JNJ

225.45

+2.18%↑

ABBV

208.78

+2.94%↑

UNH

389.05

+2.46%↑

AZN

185.25

+1.17%↑

LLY

992.82

+1.74%↑

JNJ

225.45

+2.18%↑

ABBV

208.78

+2.94%↑

UNH

389.05

+2.46%↑

AZN

185.25

+1.17%↑

LLY

992.82

+1.74%↑

JNJ

225.45

+2.18%↑

ABBV

208.78

+2.94%↑

UNH

389.05

+2.46%↑

AZN

185.25

+1.17%↑

LLY

992.82

+1.74%↑

JNJ

225.45

+2.18%↑

ABBV

208.78

+2.94%↑

UNH

389.05

+2.46%↑

AZN

185.25

+1.17%↑

Home・Lista de Ações・Ovid therapeutics Inc

Ovid therapeutics Inc

Abrir

SetorSaúde

2.79 -1.06

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2.68

Máximo

2.85

Indicadores-chave
By Trading Economics
Rendimento	22M 9.7M
Vendas	586K 718K
Margem de lucro	1,345.822
Funcionários	23
EBITDA	-152K -12M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+79.64% upside

Dividendos
By Dow Jones
Próximos Ganhos	12 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	368M 507M
Abertura anterior	3.85
Fecho anterior	2.79

Sentimento de Notícias

By Acuity

50%

175 / 346 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

0.275 / 0.33 Suporte e Resistência

Ovid therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de mai. de 2026, 22:15 UTC

Aquisições, Fusões, Aquisições de Empresas

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 de mai. de 2026, 23:46 UTC

Conversa de Mercado

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 de mai. de 2026, 23:44 UTC

Conversa de Mercado

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 de mai. de 2026, 23:33 UTC

Conversa de Mercado

Gold Rises on Possible Position Adjustments -- Market Talk

11 de mai. de 2026, 22:37 UTC

Conversa de Mercado

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 de mai. de 2026, 22:32 UTC

Ganhos

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 de mai. de 2026, 22:02 UTC

Conversa de Mercado

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 de mai. de 2026, 21:49 UTC

Ganhos

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 de mai. de 2026, 21:42 UTC

Conversa de Mercado

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 de mai. de 2026, 21:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 de mai. de 2026, 21:32 UTC

Aquisições, Fusões, Aquisições de Empresas

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 de mai. de 2026, 21:32 UTC

Aquisições, Fusões, Aquisições de Empresas

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 de mai. de 2026, 21:32 UTC

Aquisições, Fusões, Aquisições de Empresas

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 de mai. de 2026, 21:31 UTC

Aquisições, Fusões, Aquisições de Empresas

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 de mai. de 2026, 21:23 UTC

Aquisições, Fusões, Aquisições de Empresas

CSG Systems Sale to NEC Gets CFIUS Clearance

11 de mai. de 2026, 21:12 UTC

Ganhos

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 de mai. de 2026, 21:12 UTC

Ganhos

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

11 de mai. de 2026, 20:44 UTC

Ganhos

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 de mai. de 2026, 20:43 UTC

Ganhos

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 de mai. de 2026, 20:32 UTC

Ganhos

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 de mai. de 2026, 20:32 UTC

Ganhos

CleanSpark 2Q Rev $136.4M >CLSK

11 de mai. de 2026, 20:30 UTC

Ganhos

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 de mai. de 2026, 20:30 UTC

Ganhos

Steris 4Q Cont Ops EPS $2.24 >STE

11 de mai. de 2026, 20:30 UTC

Ganhos

Steris 4Q Rev $1.6B >STE

11 de mai. de 2026, 20:30 UTC

Ganhos

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 de mai. de 2026, 20:30 UTC

Ganhos

Steris 4Q Adj EPS $2.83 >STE

11 de mai. de 2026, 20:22 UTC

Ações em Alta

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 de mai. de 2026, 19:37 UTC

Ganhos

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 de mai. de 2026, 19:32 UTC

Conversa de Mercado

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Comparação entre Pares

Variação de preço

Ovid therapeutics Inc Previsão

Preço-alvo

By TipRanks

79.64% parte superior

Previsão para 12 meses

Média 5.03 USD 79.64%

Máximo 7 USD

Mínimo 4 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Ovid therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para Ovid therapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

0.275 / 0.33Suporte e Resistência

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentimento

By Acuity

175 / 346 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.